Philips, American College of Cardiology and MedAxiom Collaborate to Shape the Future of Cardiovascular Care Delivery

March 11, 2021

Royal Philips, the American College of Cardiology and MedAxiom, an ACC company with the same mission, today announced a collaboration to deliver timely and actionable information along with guidance to align physicians, operations, and finance stakeholders.

The goal of the collaboration is to drive significant performance improvements in integrated cardiovascular care in terms of the patient and care provider experience, clinical outcomes, and productivity.

Cardiovascular disease is the leading cause of death globally, taking an estimated 17.9 million lives per year [1]. In the United States alone, total costs of cardiovascular disease are expected to reach $1.1 trillion in 2035, of which direct medical costs are projected to reach $749 billion [2]. Providers who care for this population face numerous challenges, including a lack of a model for optimizing performance and a void of data or data that are not actionable. To address these challenges, Philips will leverage its cardiovascular R&D and clinical expertise, ACC will provide knowledge that leverages the skill and expertise of more than 54,000 members, and MedAxiom will contribute premier organizational performance solutions.

“The ACC is mission driven to transform cardiovascular care and improve heart health, and we embrace innovative ways of supporting clinicians and the entire cardiovascular care team,” said Cathleen C. Gates, chief executive officer, ACC. “By combining Philips’ depth of knowledge in cardiac care delivery with ACC’s robust guideline and clinical document offerings, we’re ensuring clinicians have access to guideline-driven best practices in an impactful way.”

“MedAxiom is excited to collaborate with the ACC and Philips to bring together clinical leadership and strategic alignment aimed at improving clinical, financial and operational outcomes for cardiovascular service providers,” said Gerald Blackwell, MD, MBA, FACC, president and chief executive officer, MedAxiom. “Given the rapidly changing healthcare environment, we must leverage innovative models designed not only to optimize the way care is delivered and achieve the Quadruple Aim, but to truly transform cardiovascular care.”

“As the delivery of cardiac care faces many challenges, we are implementing integrated solutions and new approaches to help make healthcare delivery more efficient and effective,” said Bert van Meurs, Executive Vice President and Chief Business Leader of Image Guided Therapy at Royal Philips. “By collaborating with ACC and MedAxiom we will advance personalized, efficient and clinically-smart cardiac care that drives optimal outcomes throughout the patient journey.”

Philips Integrated Cardiovascular Solutions – combining systems, devices, informatics and services – provide the clinical confidence needed to deliver the right care at the right time. This powerful ecosystem cuts across the full spectrum of cardiac services with the goal of optimizing length of stay while reducing readmissions, providing data integration for improved insights and procedural performance. Learnings from this work alongside those provided by the ACC and MedAxiom will empower cardiovascular service providers with data, education and services to enable providers to optimize efficiency and reduce total cost of care, while continuing to provide the highest quality levels.

Breaking down silos; driving care transformation

Built on a foundation of aligned purpose, strategic fit and complementary visions, collaboration between the organizations to bring forward longitudinal solutions and next-generation business models in cardiovascular care has already begun. Philips, the ACC and MedAxiom have identified inadequacies exposed by COVID-19 and have used this knowledge to help cardiovascular groups begin to reframe their cardiovascular care delivery. Supporting this innovation is the TRIAD Model, which since the fall of 2020 has brought together physician, healthcare administrator and industry leaders to innovate the delivery of cardiovascular care through shared accountability and shared risk. A podcast series with insights from participants in the initiative is available here.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”